SCHEMBL7923570

SCHEMBL7923570

COC(C)(C)C[N+]([O-])=Cc1ccc(F)cc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 5/20 0.35
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
ATM Q13315 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
GRIN2D O15399 2/20 0.32
GRIN3B O60391 2/20 0.32
GRIN1 Q05586 2/20 0.32
GRIN2A Q12879 2/20 0.32
GRIN2B Q13224 2/20 0.32
GRIN2C Q14957 2/20 0.32
GRIN3A Q8TCU5 2/20 0.32
FBP1 P09467 1/20 0.32
UTRN P46939 1/20 0.31
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30
KCNH2 Q12809 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7926807 0.83 POLB (0.38) NFE2L2POLBMAPTRAB9APTGS1
SCHEMBL7923592 0.82 PTGS1 (0.37) NFE2L2POLBMAPTRAB9APTGS1
SCHEMBL7921545 0.81 ACHE (0.36) NFE2L2MAPTRAB9AHTR2AHTR2C
SCHEMBL8441698 0.74 NFE2L2 (0.35) NFE2L2POLBMAPTRAB9APTGS1
SCHEMBL7923573 0.73 NFE2L2 (0.42) NFE2L2PTGS1PTGS2ATMTDP1
SCHEMBL7914607 0.71 PTGS1 (0.37) NFE2L2POLBMAPTRAB9APTGS1
SCHEMBL7914568 0.70 NFE2L2 (0.32) NFE2L2POLBMAPTRAB9APTGS1
SCHEMBL7926808 0.67 POLB (0.40) POLBMAPTRAB9APTGS1PTGS2
SCHEMBL7926748 0.65 AR (0.36) NFE2L2POLBMAPTHTR2AHTR2C
SCHEMBL11414043 0.64 ALDH1A1 (0.61) NFE2L2MAPTRAB9AATMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6194461-B1 USEFUL AS MEDICAMENT FOR TREATING RETINAL DEGENERATIVE DISORDERS; ALPHA-(2,4-DIFLUOROPHENYL)-N-T-BUTYLNITRONE, AND CORRESPONDING AMINES WHICH WOULD BE CONVERTED IN VIVO TO THE NITRONE, FOR EXAMPLE SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-02-27 US disclosed